{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-24-000140","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.233415+00:00","generated_at":"2026-05-31T14:56:04.588028+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MacroGenics receives $100M milestone payment from Incyte for retifanlimab collaboration","bullets":["MacroGenics and Incyte amended their 2017 collaboration agreement, deeming milestones achieved and triggering a $100M payment to MacroGenics.","MacroGenics confirms cash runway guidance into 2026, supported by the $100M milestone plus expected partner payments and product revenues.","Total milestones achieved from Incyte now reach $215M since the initial 2017 collaboration.","Retifanlimab (ZYNYZ) is a PD-1 inhibitor for Merkel cell carcinoma, originally developed by MacroGenics and licensed to Incyte.","MacroGenics remains eligible for up to $210M in development/regulatory milestones and $330M in commercial milestones from Incyte."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-24-000140","json":"https://secwatch.observer/filing/0001125345-24-000140.json","markdown":"https://secwatch.observer/filing/0001125345-24-000140.md","text":"https://secwatch.observer/filing/0001125345-24-000140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000140/0001125345-24-000140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000140/mgnx-20240724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:56:04.588028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}